This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
All You Need to Know About Encompass Health (EHC) Rating Upgrade to Buy
by Zacks Equity Research
Encompass Health (EHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Should Value Investors Buy Quest Diagnostics (DGX) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Encompass Health (EHC) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is ALPS O'Shares U.S. Small-Cap Quality Dividend ETF (OUSM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for OUSM
Here's Why Encompass Health (EHC) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Encompass Health (EHC) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Encompass Health (EHC) Stock Down 6% Despite Q2 Earnings Beat
by Zacks Equity Research
Encompass Health's (EHC) Q2 results reflect improved net patient revenue per discharge, partly offset by higher costs. It currently estimates 2024 adjusted EPS within $3.97-$4.22, up from the earlier view of $3.86-$4.11.
Encompass Health (EHC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Encompass Health (EHC) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Encompass Health (EHC) Q2 Earnings Beat Estimates
by Zacks Equity Research
Encompass Health (EHC) delivered earnings and revenue surprises of 9.90% and 0.25%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Encompass Health and Addus HomeCare
by Zacks Equity Research
Quest Diagnostics, DaVita, Encompass Health and Addus HomeCare have been highlighted in this Industry Outlook article.
4 Stocks to Watch From a Challenging Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, EHC and ADUS are well-poised to gain.
Astrana Health, Inc. (ASTH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Astrana Health, Inc. (ASTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Unlocking Q2 Potential of Encompass Health (EHC): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Encompass Health (EHC) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Can Cigna (CI) Beat Q2 Earnings on Growing Pharmacy Revenues?
by Zacks Equity Research
Cigna's (CI) second-quarter earnings are expected to benefit from rising premiums and pharmacy revenues, partially offset by rising expenses.
Can Humana (HUM) Navigate Rising Expenses in Q2 Earnings?
by Zacks Equity Research
Humana's (HUM) second-quarter results are expected to be impacted by declining Stand-Alone PDPs and total Specialty Medical membership levels.
Encompass Health (EHC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Encompass Health (EHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HCA Healthcare (HCA) Beats on Q2 Earnings, Ups 2024 EPS View
by Zacks Equity Research
HCA Healthcare (HCA) increases its 2024 EPS in the range of $21.60-$22.8, the midpoint implying growth of 17% from the 2023 figure.
Can Centene (CNC) Navigate Falling Memberships in Q2 Earnings?
by Zacks Equity Research
Centene's (CNC) second-quarter results are likely to reflect growing contributions from its Commercial business.
UnitedHealth Group (UNH) Q2 Earnings Beat on Strong Optum Unit
by Zacks Equity Research
UnitedHealth Group's (UNH) second-quarter earnings continue to be supported by strong Optum and UnitedHealthcare business lines. Rising medical costs partially offset the positives.
Why Encompass Health (EHC) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Encompass Health (EHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Encompass Health (EHC), Piedmont Expand Ties to Serve Georgia
by Zacks Equity Research
Encompass Health (EHC) expands its partnership with Piedmont to better serve Georgians with the Walton Rehabilitation Hospital.
Here's Why Encompass Health (EHC) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons to Retain Baxter International (BAX) in Your Portfolio Now
by Zacks Equity Research
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.